Grafa News and Videos — Page 114

United Therapeutics (NASDAQ:UTHR) received FDA clearance to proceed with a Phase 2 trial of treprostinil SMI for pulmonary hypertension associated with COPD.

Cullinan Therapeutics (NASDAQ:CGEM) and Taiho Oncology reported a 30.2% intracranial response rate for zipalertinib in 43 evaluable lung cancer patients with brain metastases.

Summit Therapeutics (NASDAQ:SMMT) announced the opening of a Phase 2 kidney cancer trial evaluating ivonescimab-based treatments in approximately 100 patients across two countries.

Veradermics (NYSE:MANE) reported positive Phase 3 results for VDPHL01, with both dosing regimens significantly increasing hair counts versus placebo after six months.

Cosmos Health (NASDAQ:COSM) forecasts approximately $15 million in fourth-quarter 2026 U.S. direct-to-consumer revenue, with projected gross profit of $10.5 million.

The forecast represents a 70% gross margin for its U.S. online business, compared with roughly 8% company-wide GAAP gross margin in Q2.

VinFast (NASDAQ:VFS) reported second-quarter 2026 revenue of $1.20 billion, up 85.5% year over year, supported by higher electric vehicle deliveries.

Peoples Bancorp of North Carolina (NASDAQ:PEBK) reported third-quarter 2026 net earnings of $5.7 million, up approximately 54% from $3.7 million a year earlier.

Alpha Tau Medical (NASDAQ:DRTS) received FDA authorization to expand its REGAIN brain cancer trial from 10 to 20 patients across three U.S. centers.

Eos Energy Enterprises (NASDAQ:EOSE) expects preliminary third-quarter 2026 revenue of US$82–US$83 million, representing 169%–172% growth from the prior year.

TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds.